Home Patent Forecast® Sectors Log In   Sign Up   Free Trial   Support   Contact   Pricing  
How it works Patent Forecast® Sectors Pricing Insights
Menu

GW Pharma Brings to Market First Cannabidiol Medication for Treating Rare Epilepsy Disorders

Z-ARCHIVE-Cannabis Patent Forecast®

February 15, 2019

GW Pharmaceuticals is the first company to bring a cannabis plant-based drug to market to treat rare forms of epilepsy. Epidiolex ® (cannabidiol or CBD) was cleared by the FDA in June 2018 for the treatment of Dravet syndrome and Lennox-Gastaut syndrome. The drug received a Fast Track designation by the FDA due to its great potential shown in successful trials with children and because at the time there were no other drugs to treat Dravet syndrome effectively. CBD has also been rescheduled as a Schedule V drug.
https://www.federalregister.gov/documents/2018/09/28/2018-21121/schedules-of-controlled-substances-placement-in-schedule-v-of-certain-fda-approved-drugs-containing


Article Source Link

GW Pharma Brings to Market First Cannabidiol Medication for Treating Rare Epilepsy Disorders


Z-ARCHIVE-Cannabis   Patent Forecast®

View Patent Forecast® Top Corporations News and Insights Data Visualization

For a blog.



301